CN112891394A

CN112891394A - Application of cinnamon extract in preparation of hypoglycemic drugs

Info

Publication number: CN112891394A
Application number: CN202110231206.5A
Authority: CN
Inventors: 李嘉; 杨海船; 张颖; 张赟赟; 陈锋; 何春欢
Original assignee: Guangxi Institute Of Chinese Medicine & Pharmaceutical Science
Current assignee: Guangxi Institute Of Chinese Medicine & Pharmaceutical Science
Priority date: 2021-03-02
Filing date: 2021-03-02
Publication date: 2021-06-04

Abstract

The invention discloses an application of a cinnamon extract in preparation of a hypoglycemic drug, and belongs to the technical field of medicines. When the dosage of the cinnamon extract B is 360mg/kg, the blood sugar of a diabetic mouse caused by STZ can be obviously reduced, and the blood sugar reduction rate is 36.5%; the cinnamon extract is used for reducing blood sugar, and a thought and a theoretical basis are provided for researching and developing a new medicament for treating diabetes.

Description

Application of cinnamon extract in preparation of hypoglycemic drugs

Technical Field

The invention relates to the technical field of medicines, in particular to application of a cinnamon extract in preparation of a hypoglycemic drug.

Background

Diabetes is one of the high-grade diseases in the society of today, and is becoming younger and more popular. Diabetes is mainly divided into two categories: type I diabetes is a lymphocyte-mediated autoimmune disease, and is a multifactorial disease caused by the joint participation and/or interaction of multiple risk factors such as heredity, environment, behavior and the like. Type ii diabetes is a common chronic disease with high blood glucose levels as the major hallmark. Generally, due to the interaction of genetic factors and environmental factors, the absolute or relative insulin secretion is insufficient or the sensitivity of target tissues to insulin is reduced, and then a series of metabolic disorder syndromes of fat, protein, water, electrolyte and the like are caused, and the influence is more serious. The type II diabetes needs to be taken for a lifetime, and adverse reactions of western medicines also occur, so that a plurality of organ injuries and even death are caused to a patient. In recent years, scholars at home and abroad continuously search for active ingredients for reducing blood sugar in Chinese herbal medicines. The traditional Chinese medicine has small toxic and side effects, is often acted on multiple targets simultaneously, and generally has the functions of regulating blood fat, protecting liver, resisting oxidation and the like.

Cinnamon (Cinnsmomum cassia Presl), ginseng and pilose antler are three medical rarities which are advocated by the Chinese medical field, and have the effects of nourishing kidney, dispelling cold and prolonging life. Cinnamon is used as a food used as both medicine and food, and is widely applied to Chinese patent medicines and spices at present. In Guangxi, cinnamon is also a common herb and food material for Guangxi Zhuang and Yao people. Modern pharmacological research shows that cinnamon has various pharmacological effects of relieving fever, easing pain, resisting inflammation, resisting tumor, resisting ulcer, resisting diarrhea, benefiting gallbladder and the like, and also has good curative effect on diseases of a digestive system, a cardiovascular system and an immune system.

Therefore, providing the application of cinnamon extract in preparing hypoglycemic drugs is a problem that needs to be solved urgently by those skilled in the art.

Disclosure of Invention

In view of the above, the present invention provides an application of cinnamon extract in preparing hypoglycemic drugs.

In order to achieve the purpose, the invention adopts the following technical scheme:

application of cortex Cinnamomi extract in preparing medicine for lowering blood sugar is provided.

Further, the preparation method of the cinnamon extract comprises the following steps:

(1) pulverizing cortex Cinnamomi, placing into volatile oil extractor, adding water at a weight-volume ratio of 1:8 (kg/L), and collecting volatile oil by steam distillation to obtain cortex Cinnamomi extract A;

(2) collecting cortex Cinnamomi extract A, purifying with D101 macroporous resin column, washing with water, discarding water solution, washing with 70% ethanol, and recovering solvent to obtain cortex Cinnamomi extract B (trans-cinnamaldehyde).

According to the technical scheme, compared with the prior art, the invention discloses the application of the cinnamon extract in preparing the hypoglycemic drug, when the dosage of the cinnamon extract B is 360mg/kg, the blood sugar of a diabetic mouse caused by STZ can be obviously reduced, and the blood sugar reduction rate is 36.5%; the cinnamon extract is used for reducing blood sugar, and a thought and a theoretical basis are provided for researching and developing a new medicament for treating diabetes.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.

FIG. 1 is a HPLC chromatogram of cinnamon extract A (cinnamon oil) according to the present invention;

FIG. 2 is an HPLC chromatogram of cinnamon extract B (trans-cinnamaldehyde) according to the present invention.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1 cinnamon extract sample preparation

Pulverizing cortex Cinnamomi, placing into volatile oil extractor, adding water at a ratio of 1:8, and collecting volatile oil by steam distillation to obtain cortex Cinnamomi extract A (oleum Cinnamomi).

Collecting cortex Cinnamomi extract A, purifying with D101 macroporous resin column, washing with water, discarding water solution, washing with 70% ethanol, and recovering solvent to obtain cortex Cinnamomi extract B (trans-cinnamaldehyde).

HPLC detection of cortex Cinnamomi extract A is shown in FIG. 1; HPLC analysis of cinnamon extract B was shown in FIG. 2.

Example 2 examination of the Effect of cinnamon extract A and cinnamon extract B on Streptozotocin (STZ) -induced diabetic mice

(1) Drugs and dosage of drugs

Cinnamon extract a: 1.2, 0.6 and 0.3g/kg, which are equivalent to 85.9, 42.9 and 21.5g/kg of crude drugs, wherein the content of cinnamon extract B is 32.02 percent.

And (3) cinnamon extract B: 360. 180 and 90mg/kg, and the purity is 95.08 percent by liquid chromatography detection.

Positive drugs: metformin 320 mg/kg.

(2) Molding and method

90 Kunming mice with SPF grade, half male and female, weight (20 +/-2) g are taken, fasting is carried out for 12h before molding, 10 mice are randomly extracted to be used as blank control groups, and the other mice are respectively injected with STZ 150mg/kg in the abdominal cavity. And (5) collecting blood after 72 hours to measure the FBG of the mouse, and selecting the mouse with the FBG of more than 11.1mol/L as a mouse successfully modeled. Successfully molded mice were randomly assigned into 8 groups of 10 mice each. Model group, positive control group, cinnamon extract A high, medium and low dosage group, and cinnamon extract B high, medium and low dosage group. After the model is formed, the stomach is perfused once in the morning, the normal saline is perfused into the stomach of the model group and the control group, and the stomach is perfused for 15 days continuously in each group. Fasting is carried out for 12h before 15d final administration, eyeball drawing and blood drawing are carried out after 1h of administration, and serum is centrifuged to be tested. Glucose oxidase method is adopted for blood sugar measurement, radioimmunoassay method is adopted for insulin measurement, and Insulin Sensitivity Index (ISI) and Insulin Resistance (IR) are calculated; TG, TC, LDL-C, HDL-C were measured strictly according to the kit instructions.

(3) Results

Influence of cinnamon extract A and cinnamon extract B on Fasting Blood Glucose (FBG) of mice caused by STZ

FBG was measured before and after administration to each group of mice, and the results are shown in Table 1.

TABLE 1 Effect of cinnamon extract A and B on STZ-induced mouse FBG ((S))

n＝10)

Note:^＊p in comparison with blank control<0.05；^△In comparison with model group, p<0.05。

The results in table 1 show that cinnamon extract a and cinnamon extract B can significantly reduce blood sugar in STZ-induced diabetic mice. Before administration, compared with a blank control group, the FBG of the mice in the model group and other groups is obviously increased; after administration, FBG decreased in all other groups of mice, but was higher in all groups of diabetic mice than in the placebo group.

② the influence of cinnamon extract A and cinnamon extract B on fasting insulin (FNS) of diabetic mice caused by STZ

FNS, ISI, IR were determined for each group of mice and the results are shown in table 2.

TABLE 2 Effect of cinnamon extract A and B on FNS, ISI and IR in STZ-induced diabetic mice (II)

n＝10)

The results in Table 2 show that insulin resistance is developed due to abnormally increased insulin levels in each of the other groups compared to the control group. After administration, the FNS levels in the metformin group and other groups were significantly reduced compared to the model group. Compared with the model group, the metformin group and the cinnamon extract A high, medium and low dose groups have improved ISI of the cinnamon extract B high, medium and low dose groups; the IR of the metformin group and cinnamon extract A high, medium and low dose groups, and cinnamon extract B high, medium and low dose groups was decreased.

③ the influence of the cinnamon extract A and the cinnamon extract B on the fasting plasma lipid of the STZ-induced diabetic mice is measured to determine the TG, TC and LDL-C, HDL-C of each group of mice, and the result is shown in Table 3.

TABLE 3 Effect of cinnamon extract A and cinnamon extract B on TG, TC and LDL-C, HDL-C in STZ-induced diabetic mice (for treatment of diabetes mellitus) ((for treatment of diabetes mellitus))

n＝10)

The results in Table 3 show that, compared with the blank control group, TG was increased in the model group and each administration group, TC was increased in the model group and each administration group, LDL-C was increased in the model group and each administration group, and HDL-C was decreased in the model group and each administration group; compared with the model group, TG, TC and LDL-C of each group are all reduced, and HDL-C is increased. The results suggest that cinnamon extract A and cinnamon extract B may have antioxidant effect and enhance immune function to regulate blood lipid of diabetic mice and improve metabolic disorder of blood lipid of mice caused by STZ.

The cinnamon extract A and the cinnamon extract B both have a good blood sugar reducing effect, wherein the cinnamon extract B is probably a main effective substance of the cinnamon volatile oil for reducing the blood sugar. In the test of the effect of cinnamon extract on STZ-induced diabetic mice, after administration, FBG was reduced in the model group and other groups of mice, but compared with the blank control group, FBG was higher in each group of diabetic mice than in the blank control group. The FNS level of the metformin group and other groups is obviously reduced compared with that of the model group. Compared with the model group, the ISI of the metformin group and the cinnamon extract A high, medium and low dose groups is improved, and the IR of the metformin group and the cinnamon extract A high, medium and low dose groups and the cinnamon extract B high, medium and low dose groups is reduced. In addition, the cinnamon extract A and the cinnamon extract B can have the effects of resisting oxidation, enhancing the immune function, regulating the blood fat of a diabetic mouse and improving the metabolic disorder of the blood fat of the mouse caused by STZ.

The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of cortex Cinnamomi extract in preparing medicine for lowering blood sugar is provided.

2. The use of the cinnamon extract according to claim 1 for preparing a hypoglycemic medicament, wherein the cinnamon extract is prepared by the following steps:

(1) pulverizing cortex Cinnamomi, placing into volatile oil extractor, adding water at a ratio of 1:8, and collecting volatile oil by steam distillation to obtain cortex Cinnamomi extract A;

(2) and (3) putting the cinnamon extract A on a D101 macroporous resin column, washing with water, discarding water liquid, washing with 70% ethanol, and recovering the solvent to obtain a cinnamon extract B.